PALISADE BIO, INC.

Company Overview We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 ( PDE4 ) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease ( IBD ), including ulcerative colitis ( UC ) and Crohn’s disease ( CD ). Our Strategy We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. We believe the key elements of our strategy include: advancing our lead clinical product candidate, PALI-2108, towards a Phase 2 clinical study in UC designed to evaluate clinical remission response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission; the completion of early studies in FSCD to further characterize PALI-2108's safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications; leveraging our drug development platform infrastructure to identify product candidates that target inflammatory and fibrotic diseases; pursuing strategic partnerships to further expand our programs and maximize the worldwide potential of our product candidates and platform; and pursuing in-licensing/acquisitions of new product candidates or out-licensing/sales of our existing product candidates.